Johanna Friedl-Naderer - Mar 2, 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Business Officer, Global
Signature: /s/ Howard Horn, Attorney-in-Fact
Stock symbol: VIR
Transactions as of: Mar 2, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/8/2022, 10:35 AM
Next filing: Feb 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+90K		$0.00	90K	Mar 2, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+45K		$0.00	45K	Mar 2, 2022	Common Stock	45K	$24.13	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	25% of the shares subject to the stock option vest and become exercisable on March 2, 2023, and the remainder vest in 36 equal monthly installments thereafter.